Work

Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.108

Authors: Alexander E. Drilon, D. Ross Camidge, Sai-Hong Ignatius Ou, Jeffrey William Clark, Mark A. Socinski, Jared Weiss, Gregory J. Riely, Maria Winter, Sherry C. Wang, Katherine Monti, Keith D. Wilner, Paul K. Paik

Institutions: Memorial Sloan Kettering Cancer Center, University of California, Irvine, Massachusetts General Hospital, University of Pittsburgh Medical Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Pfizer (United States), Rho (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2681380026

Cites:

Cited by: 114

Related to: 10